Polypid Ltd (PYPD) Stock Price, Quote & News

Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 4719 5700

Website: www.polypid.com

Address:

18 Hasivim Street, Petah Tikva, Israel

PandaSwingz Feb. 26 at 12:57 AM

$PYPD

0 · Reply

WallStWireAds Feb. 25 at 3:57 PM

$PYPD https://www.globenewswire.com/news-release/2026/02/25/3244614/0/en/PolyPid-Announces-Participation-in-Upcoming-Investor-Conferences.h

0 · Reply

Syndr78 Feb. 25 at 5:14 AM

$PYPD interesting and positive fundamentals... With the major MAJOR exception being a minimal cash runway. Dilution is therefore and unfortunately all but certain.

0 · Reply

Finnish_boy Feb. 24 at 11:08 PM

$PYPD TWO WEEKS TIME TO LOAD UP THE STOCK. Mid-March --> is very risky time for big news (US PARTNER + NDA FIRST SUBMISSION)

0 · Reply

Finnish_boy Feb. 24 at 11:04 PM

$PYPD I lost 20% of my portfolio on risky bet on GOSS. It was calculated risk and i was wrong on my assumptions. I will never invest in clinical stages (pre readout) bios, too risky and complicated for me, i have no edge. If i had won, i wouldnt still invest in pre readout bios anymore. Do you know where i can get my money? Yes, IT'S PYPD.

0 · Reply

topstockalerts Feb. 24 at 10:25 PM

After Hours Top Gainers PT2 $ABCL $RETO $AXON $BNAI $PYPD

0 · Reply

Finnish_boy Feb. 21 at 12:52 PM

$PYPD Here’s the timeline: March: US partner March: CMC/nonclinical modules (first NDA submission) May: Clinical module (final NDA submission) June: Kynatrix platform preclinical data H2: MAA submission Late Q4-early 2027: FDA approval IMO stock goes up in March a lot. And latest by June $10 stock. I will load up this baby in 2 weeks. Already my biggest position.

1 · Reply

BillionerOfKing Feb. 20 at 6:45 PM

$PYPD Current Stock Price: $4.20

0 · Reply

Finnish_boy Feb. 20 at 3:31 PM

$PYPD Bought more $4.25. my biggest dream this drops under $4 .. next month epic. Us partner and NDA submission. H1 PT $10

0 · Reply

AdaKaul628 Feb. 18 at 1:52 PM

$PYPD Payment services exposure with margin pressure.

2 · Reply

PolyPid Announces Participation in Upcoming Investor Conferences

Feb 11, 2026, 3:24 PM EST - 15 days ago

PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript

Feb 11, 2026, 7:30 AM EST - 15 days ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Jan 28, 2026, 8:00 AM EST - 4 weeks ago

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Dec 16, 2025, 8:30 AM EST - 2 months ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dec 10, 2025, 4:42 PM EST - 2 months ago

PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript

Dec 3, 2025, 8:30 AM EST - 3 months ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

Nov 25, 2025, 8:30 AM EST - 3 months ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Nov 12, 2025, 12:51 PM EST - 3 months ago

PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:30 AM EST - 3 months ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:30 AM EST - 4 months ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Oct 29, 2025, 8:30 AM EDT - 4 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Sep 30, 2025, 8:45 AM EDT - 5 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 17, 2025, 8:44 AM EDT - 5 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 16, 2025, 8:30 AM EDT - 5 months ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 3, 2025, 8:30 AM EDT - 6 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 6 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Aug 13, 2025, 4:52 PM EDT - 7 months ago

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:30 AM EDT - 7 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 8:00 AM EDT - 7 months ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Jul 30, 2025, 8:00 AM EDT - 7 months ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 15, 2025, 8:00 AM EDT - 8 months ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jun 16, 2025, 7:20 PM EDT - 9 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 11, 2025, 9:42 AM EDT - 9 months ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 9 months ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 9, 2025, 8:54 AM EDT - 9 months ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 7:30 AM EDT - 9 months ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 6, 2025, 4:05 PM EDT - 9 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

May 30, 2025, 10:12 AM EDT - 9 months ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 20, 2025, 7:00 AM EDT - 10 months ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 14, 2025, 1:24 PM EDT - 10 months ago

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:00 AM EDT - 10 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 10 months ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 22, 2025, 7:00 AM EDT - 11 months ago

PolyPid to Participate in The Citizens Life Sciences Conference

Mar 11, 2025, 7:00 AM EDT - 1 year ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 3, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the 37th Annual ROTH Conference

Feb 12, 2025, 10:44 AM EST - 1 year ago

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 30, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Dec 26, 2024, 10:31 AM EST - 1 year ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

Dec 23, 2024, 7:22 PM EST - 1 year ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 13, 2024, 2:06 PM EST - 1 year ago

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

PandaSwingz Feb. 26 at 12:57 AM

$PYPD

0 · Reply

WallStWireAds Feb. 25 at 3:57 PM

$PYPD https://www.globenewswire.com/news-release/2026/02/25/3244614/0/en/PolyPid-Announces-Participation-in-Upcoming-Investor-Conferences.h

0 · Reply

Syndr78 Feb. 25 at 5:14 AM

$PYPD interesting and positive fundamentals... With the major MAJOR exception being a minimal cash runway. Dilution is therefore and unfortunately all but certain.

0 · Reply

Finnish_boy Feb. 24 at 11:08 PM

$PYPD TWO WEEKS TIME TO LOAD UP THE STOCK. Mid-March --> is very risky time for big news (US PARTNER + NDA FIRST SUBMISSION)

0 · Reply

Finnish_boy Feb. 24 at 11:04 PM

0 · Reply

topstockalerts Feb. 24 at 10:25 PM

After Hours Top Gainers PT2 $ABCL $RETO $AXON $BNAI $PYPD

0 · Reply

Finnish_boy Feb. 21 at 12:52 PM

1 · Reply

BillionerOfKing Feb. 20 at 6:45 PM

$PYPD Current Stock Price: $4.20

0 · Reply

Finnish_boy Feb. 20 at 3:31 PM

$PYPD Bought more $4.25. my biggest dream this drops under $4 .. next month epic. Us partner and NDA submission. H1 PT $10

0 · Reply

AdaKaul628 Feb. 18 at 1:52 PM

$PYPD Payment services exposure with margin pressure.

2 · Reply

CARTE_BLANCHE_DEVEREAUX Feb. 17 at 9:47 PM

$ANRO $ALT $PYPD When I first bought into ANRO, I thought I was being reckless. I worried that I had bought too much... Now.... I realize I didn't buy enough. Won't make the same mistake with POLYPID.

0 · Reply

Botmax Feb. 17 at 9:41 PM

$PYPD Early stage? How to tell us you have done zero DD.

0 · Reply

OfficialStocktwitsUser Feb. 17 at 3:53 PM

$PYPD RSI: 41.07, MACD: 0.0357 Vol: 0.15, MA20: 4.61, MA50: 4.37 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

bullishnoah Feb. 17 at 8:33 AM

$PYPD Pre-revenue biotech; early-stage

0 · Reply

lelXYpics Feb. 16 at 5:14 AM

$PYPD https://www.theglobeandmail.com/investing/markets/stocks/DXCM/pressreleases/224745/analysts-are-bullish-on-top-healthcare-stocks-polypid-pypd-dexcom-dxcm/

0 · Reply

pandodark Feb. 15 at 11:01 PM

$PYPD Did a little digging into the new Chairman. Not sure this was the right choice. Seems more of a senior manager not C-Level or someone who can steer the ship… Thoughts please.

1 · Reply

WallStWireAds Feb. 12 at 2:15 PM

$PYPD The Infection Problem Surgery Still Can’t Solve – and the Opportunity in Addressing It >> https://calypsoresearch.com/PYPD/120226

0 · Reply

Finnish_boy Feb. 12 at 12:11 PM

$PYPD Amazing report. There were several things i liked. I am now quiet until big news. I will buy more shares during February. Price action can be between $4 and $5 in a month and then skyrocket. My H1 PT is $10.

1 · Reply

History101 Feb. 12 at 5:32 AM

$PYPD 926 watching 2/11/2026

0 · Reply

dm4 Feb. 11 at 10:43 PM

$PYPD https://finance.yahoo.com/news/polypid-ltd-pypd-q4-2025-210320091.html

0 · Reply

dm4 Feb. 11 at 10:43 PM

$PYPD GLP-1 - “We are already in discussion with potential partners”!! “Q: How do you plan to strategically approach the GLP-1 program, and when might a partnership be considered? A: Diklachat Axelblad, CEO: We aim to partner at an early stage, building robust pre-clinical efficacy and PK data. Our GLP-1 program leverages our new Kinetrix technology for sustained release, targeting improved patient compliance. We are already in discussions with potential partners.”

0 · Reply

StocktwitsEarnings Feb. 11 at 1:32 PM

$PYPD Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.41 up 63.72% YoY • PolyPid anticipates beginning its rolling NDA submission for D-PLEX100 by the end of the first quarter of 2026. The company believes its cash balance will fund operations into the second half of 2026 through significant milestones.

0 · Reply

Market Cap	67.56M
Revenue (ttm)	0.00
Net Income (ttm)	-34.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.09

Volume	58,019
Avg Vol	66,382
Day's Range	N/A - N/A
Shares Out	15.90M
Stochastic %K	38%
Beta	1.52
Analysts	Strong Sell
Price Target	$12.25